The XPD Lys751Gln Polymorphism has Predictive Value in Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Systemic Review and Meta-analysis |
Qian, Ying-Ying
(Department of Oncology, The First Affiliated Hospital of Nanjing Medical University)
Liu, Xin-You (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) Pei, Dong (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Xu, Jia-Li (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Shen, Hua (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Chen, Xiao-Feng (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Liu, Yi-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Shen, Li-Zong (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) Shu, Yong-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) |
1 | Ahmad S (2010). Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers, 7, 543-66. DOI |
2 | Altman DG, Bland JM (2003). Interaction revisited: the difference between two estimates. BMJ, 326, 219. DOI |
3 | Balboa E, Duran G, Lamas MJ, et al (2010). Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics, 11, 747-61. DOI |
4 | Boige V, Mendiboure J, Pignon JP, et al (2010). Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol, 28, 2556-64. DOI |
5 | Chen YC, Tzeng CH, Chen PM, et al (2010). Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci, 101, 530-5. DOI |
6 | Chen YM, Wu XL, Zhang LW, et al (2012). Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients. Zhonghua Zhong Liu Za Zhi, 34, 501-5 (in Chinese). |
7 | Dybdahl M, Vogel U, Frentz G, et al (1999). Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev, 8, 77-81. |
8 | Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, et al (2010). Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol, 69, 58-66. DOI |
9 | Faivre S, Chan D, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37. DOI |
10 | Farina Sarasqueta A, van Lijnschoten G, Lemmens VE, et al (2011). Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol Diagn Ther, 15, 277-83. DOI |
11 | Fuss JO, Tainer JA (2011). XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. DNA Repair (Amst), 10, 697-713. DOI |
12 | Gan Y, Li X-R, Chen D-J, et al (2012). Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a chinese population. Asian Pac J Cancer Prev, 13, 5721-4. 과학기술학회마을 DOI |
13 | Haller DG, Tabernero J, Maroun J, et al (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol, 29, 1465-71. DOI ScienceOn |
14 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
15 | Kang S, Sun HY, Zhou RM, et al (2013). DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy. Asian Pac J Cancer Prev, 14, 941-6. 과학기술학회마을 DOI ScienceOn |
16 | Keam B, Im SA, Han SW, et al (2008). Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer, 8, 148. DOI |
17 | Kuebler JP, Wieand HS, O'Connell MJ, et al (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol, 25, 2198-204. DOI ScienceOn |
18 | Kumamoto K, Ishibashi K, Okada N, et al (2013). Polymorphisms of , and -3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett, 6, 648-54. |
19 | Lai JI, Tzeng CH, Chen PM, et al (2009). Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci, 100, 1261-6. DOI |
20 | Lamas MJ, Duran G, Balboa E, et al (2011). Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics, 12, 433-42. DOI |
21 | Le Morvan V, Smith D, Laurand A, et al (2007). Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics, 8, 1693-703. DOI |
22 | Lee KH, Chang HJ, Han SW, et al (2013). Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol, 71, 843-51. DOI |
23 | Leichman LP, Goldman BH, Bohanes PO, et al (2011). S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol, 29, 4555-60. DOI |
24 | Li H-Y, Ge X, Huang G-M, et al (2012). GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population. Asian Pac J Cancer Prev, 13, 3465-9. 과학기술학회마을 DOI |
25 | Lunn RM, Helzlsouer KJ, Parshad R, et al (2000). XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis, 21, 551-5. DOI |
26 | Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5. DOI ScienceOn |
27 | Martinez-Balibrea E, Abad A, Aranda E, et al (2008). Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer, 44, 1229-37. DOI |
28 | McLeod HL, Sargent DJ, Marsh S, et al (2010). Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol, 28, 3227-33. DOI |
29 | Monzo M, Moreno I, Navarro A, et al (2007). Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology, 72, 364-70. DOI ScienceOn |
30 | Moreno V, Gemignani F, Landi S, et al (2006). Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res, 12, 2101-8. DOI ScienceOn |
31 | Pare L, Marcuello E, Altes A, et al (2008). Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer, 99, 1050-5. DOI |
32 | Park DJ, Stoehlmacher J, Zhang W, et al (2001). A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res, 61, 8654-8. |
33 | Ruzzo A, Graziano F, Loupakis F, et al (2007). Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol, 25, 1247-54. DOI ScienceOn |
34 | Spitz MR, Wu X, Wang Y, et al (2001). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res, 61, 1354-7. |
35 | Stoehlmacher J, Park DJ, Zhang W, et al (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54. |
36 | Sun XH, Hou WG, Zhao HX, et al (2013). Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors. Asian Pac J Cancer Prev, 14, 2049-52. DOI ScienceOn |
37 | Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst, 92, 205-16. DOI ScienceOn |
38 | Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. DOI ScienceOn |
39 | Wang LE, Gorlova OY, Ying J, et al (2013). Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. Cancer Res, 73, 256-64. |
40 | Wolfe KJ, Wickliffe JK, Hill CE, et al (2007). Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics, 17, 897-905. DOI |
41 | Yin M, Yan J, Martinez-Balibrea E, et al (2011). ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res, 17, 1632-40. DOI |
42 | Yu YJ, Li YM, Hou XD, et al (2012). Effect of tissue factor on invasion inhibition and apoptosis inducing effect of oxaliplatin in human gastric cancer cell. Asian Pac J Cancer Prev, 13, 1845-9. 과학기술학회마을 DOI |
43 | Zhang ZY, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6. 과학기술학회마을 DOI ScienceOn |
44 | Zintzaras E (2010). The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol, 9, 21. |
![]() |